Featured Product New!: Monoclonal Antibodies to Coronavirus SARS-CoV-2 RBD Domain
Reference: A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV, Science 03 Apr 2020:eabb7269, DOI: 10.1126/science.abb7269
Researchers from around the world have asked LifeTein for providing peptides to develop vaccines targeting the novel coronavirus (2019-nCoV) or SARS-CoV-2.
LifeTein synthesized the receptor-binding motif (RBM) in 6 days. This is part of the receptor-binding domain (RBD). It is a critical determinant of virus-receptor interaction and thus of viral host range and tropism. The RBD also includes important viral-neutralizing epitopes (21–23), and it may be sufficient to raise a protective antibody response in inoculated animals.
A total of nine cysteine residues are found in the RBD, six of which forming three pairs of disulfide bonds. Among these three pairs, two are in the core (Cys336-Cys361 and Cys379-Cys432) to help stabilize the beta sheet structure while the remaining one (Cys480-Cys488) connects loops in the distal end of the RBM.
Studies showed that the sequence of 2019-nCoV coronavirus RBD, including its receptor -binding motif (RBM) that directly contacts ACE2 and uses ACE2 as its receptor with much higher affinity (10-20 times higher!) than SARS.
Peptide sequence: SNNLDSKVGG NYNYLYRLFR KSNLKPFERD ISTEIYQAGS TPCNGVEGFN CYFPLQSYGF QPTNGVGYQ
Modifications: N-Terminal: Biotin Labeling, Disulfide Bridge: Cys480-Cys488
Molecular Weight: 8052.94
Download Data File:HPLC